Mritargeted or Standard Biopsy in Prostate Cancer Screening

Lung cancer is the second most diagnosed cancer and remains the leading cause of cancer-related deaths in the United States. The high mortality is largely the consequence of late diagnosis; lung cancer is typically asymptomatic in early stages when a surgical cure is most likely. As a result, there has been great interest in and research on early detection of lung cancer through screening.

This book, now in an extensively revised second edition, provides an exhaustive review of the state of the art in the management of prostate cancer, from screening to treatment, with emphasis on a multidisciplinary approach. The editors are very excited about the outstanding new or updated contributions from the different expert authors.

This text encompass an up-to-date, comprehensive review of the state-of-the-art for gland preserving therapies. Fully updated and revised, this text evaluates the scientific evidence for the evolving trend to treat intermediate risk, clinically localized prostate cancer in a focally ablative manner with novel gland-preserving, focal therapy methods. Various ablative devices such as high intensity focused ultrasound, irreversible electroporation, photodynamic therapy, cryotherapy and laser ablation, among others, is discussed in regard to their strengths and limitations as a therapeutic modality. Emphasis is placed on patient selection and outcomes utilizing both advanced imaging techniques and pathologic evaluation.